🔎 Trials Near Me

Hjem › Akut myelogen leukemi › Alabama › Birmingham

Kliniske studier for Akut myelogen leukemi i Birmingham, AL

21 studier for Akut myelogen leukemi søker deltakere på steder i og rundt Birmingham (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.

Offisiell studietekst (engelsk)

Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

RekruttererFase 2
  • University of Alabama at Birmingham Cancer Center, Birmingham
Alder 18 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT05564390

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • University of Alabama at Birmingham Cancer Center, Birmingham
Alder 18 til 59 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

RekruttererFase 3
  • University of Alabama at Birmingham, Birmingham
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06852222

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • University of Alabama at Birmingham Cancer Center, Birmingham
Alder 18 til 59 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • University of Alabama at Birmingham Cancer Center, Birmingham
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

RekruttererFase 3
  • Children's Hospital of Alabama, Birmingham
6 Months – 21 Years · Alle kjønn · Oppdatert 17. sep. 2026 · NCT04293562

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

RekruttererFase 2
  • University of Alabama - Birmingham, Birmingham
Alder 18 og eldre · Alle kjønn · Oppdatert 16. sep. 2026 · NCT06824168

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

RekruttererFase 3
  • Children's Hospital of Alabama, Birmingham
Alder 1 til 25 · Alle kjønn · Oppdatert 4. sep. 2026 · NCT07022678

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

RekruttererFase 1/2
  • O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham
Alder 12 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT04588922

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

RekruttererFase 2/3
  • University of Alabama Birmingham, Birmingham
Alder 18 til 80 · Alle kjønn · Oppdatert 5. aug. 2026 · NCT06788756

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

RekruttererObservasjonsstudie
  • University of Alabama at Birmingham, Birmingham
Alle aldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT01351545

A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers

Rekrutterer
  • University of Alabama at Birmingham, Division of Hematology and Oncology, Birmingham
Alder 60 og eldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT06697600

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

RekruttererFase 1
  • University of Alabama at Birmingham, Birmingham
Alder 18 til 75 · Alle kjønn · Oppdatert 4. mar. 2026 · NCT07044544

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

RekruttererFase 1
  • University of Alabama O'Neal Cancer Center, Birmingham
Alder 18 og eldre · Alle kjønn · Oppdatert 16. jan. 2026 · NCT05143996

HPC Offered for PRESERVE Expansion

RekruttererObservasjonsstudie
  • University of Alabama, Birmingham, Birmingham
Alder 12 til 80 · Alle kjønn · Oppdatert 28. aug. 2025 · NCT07145411

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

RekruttererFase 1/2
  • The Kirklin Clinic of UAB Hospital, Birmingham
Alder 18 og eldre · Alle kjønn · Oppdatert 26. aug. 2025 · NCT03850574

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

RekruttererFrivillige helsepersonell ønskes velkommen
  • University of Alabama - Birmingham, Birmingham
Alder 18 til 120 · Alle kjønn · Oppdatert 25. jul. 2025 · NCT05237258

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

RekruttererFase 1
  • University of Alabama at Birmingham, Birmingham
Alder 18 og eldre · Alle kjønn · Oppdatert 15. nov. 2024 · NCT06034275

Akut myelogen leukemi-studier i andre byer

Andre studier i Birmingham

Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.